Autolus Therapeutics plc (AUTL) Stock Price & Analysis
Autolus Therapeutics plc (AUTL) — MoonshotScore 15/100 (Weak band), calculated Nov 18, 2026. Price $0.9073 (-7.38%), as of the Nov 20, 2026 trading session; market cap $242M.
Educational signal · not a buy or sell recommendation · How to read this
Autolus Therapeutics plc · AUTL · NASDAQ
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in T-cell-based immunotherapies for various cancers.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Autolus Therapeutics (AUTL)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Only growth holds up — quality and the balance sheet are near the sector floor; far more to fix here than to build on, and it’s expensive on top. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Compounding; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 3 reports
- Altman Z -4.21 · Piotroski F 3
Holding back: weak fundamentals, balance-sheet strain, a rich price
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 15 | Weak | |
| 15 | Weak | |
| 15 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.9073 | |
| Change on the day | -7.38% | |
| 52-week range | $0.9073 – $2.58 | |
| Market capitalisation | $242M | — |
| Price / earnings (trailing) | -1.81 | |
| Shares traded on the day | 3.90M |
Price & events
Other perspectives
Council score for Autolus Therapeutics (AUTL): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Autolus Therapeutics (AUTL), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Autolus Therapeutics plc (AUTL) is listed on NASDAQ. It employs 752 people and is led by Christian Martin Itin. The market values it at $242M.
What do the latest results show for Autolus Therapeutics (AUTL)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $21M | -$79M | -$0.30 (diluted) |
| Q4 FY2025 | $24M | -$90M | — |
| Q1 FY2026 | $26M | -$72M | -$0.27 (diluted) |
| Q2 FY2026 | $46M | -$39M | -$0.15 (diluted) |
What are the financial strengths and risks for Autolus Therapeutics (AUTL)?
Short answer
The MoonshotScore pillars rate durable growth as strengths. What is holding it back is weak fundamentals, balance-sheet strain, a rich price. The distress and quality screens read Altman Z -4.21 · Piotroski F 3. Trailing ratios: ROA -22.5% · current ratio 3.72.
Data-derived red flags
- Listing risk — at $0.9073 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -4.21 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How does Autolus Therapeutics compare with its peers?
Short answer
Autolus Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Autolus Therapeutics (AUTL) — this page | $0.9073 | $242M | 15 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AUTL in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AUTL in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Autolus Therapeutics (AUTL)?
- Autolus Therapeutics PLC (AUTL) (Q3 2026) Earnings Call Highlights: AUCATZYL Revenue Nearly ...
- Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
- Autolus Therapeutics Reports Third Quarter 2026 Financial Results
- Autolus Therapeutics Q3 Earnings Call Highlights
Investor Questions: AUTL Stock
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for AUTL?
AUTL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is AUTL a good stock to buy?
Stock Expert AI does not rate AUTL buy, sell or hold. Autolus Therapeutics plc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AUTL stock price today?
The last price recorded for Autolus Therapeutics plc (AUTL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for AUTL?
Autolus Therapeutics plc (AUTL) holds a MoonshotScore in the low range. Not financial advice.
How frequently does AUTL data refresh on this page?
AUTL's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AUTL's recent stock price performance?
Autolus Therapeutics plc (AUTL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust clinical pipeline with multiple T-cell immunotherapy candidates targeting various cancers. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AUTL overvalued or undervalued right now?
Autolus Therapeutics plc (AUTL) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research AUTL before investing?
Before investing in Autolus Therapeutics plc (AUTL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AUTL to a portfolio?
Key strength of Autolus Therapeutics plc (AUTL): Robust clinical pipeline with multiple T-cell immunotherapy candidates targeting various cancers. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 6 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com